Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.